ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Significant Decline in Short Interest

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 220,000 shares, a decline of 25.0% from the January 15th total of 293,400 shares. Approximately 2.0% of the company’s shares are sold short. Based on an average trading volume of 197,200 shares, the short-interest ratio is currently 1.1 days.

ABVC BioPharma Stock Up 8.9 %

Shares of NASDAQ ABVC opened at $0.46 on Friday. ABVC BioPharma has a 52-week low of $0.40 and a 52-week high of $1.73. The firm has a fifty day moving average of $0.52 and a 200-day moving average of $0.59. The stock has a market capitalization of $5.93 million, a PE ratio of -0.53 and a beta of 0.67.

Institutional Trading of ABVC BioPharma

A hedge fund recently raised its stake in ABVC BioPharma stock. Avantax Planning Partners Inc. increased its holdings in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) by 269.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 143,968 shares of the company’s stock after purchasing an additional 104,968 shares during the period. Avantax Planning Partners Inc. owned 1.11% of ABVC BioPharma worth $85,000 as of its most recent filing with the Securities and Exchange Commission. 11.38% of the stock is owned by hedge funds and other institutional investors.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.